{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Grade 3-4 toxicities by the Bearman common toxicity criteria, encountered by younger (\\< 56 years old) advanced multiple myeloma patients treated with melphalan, IL2-incubated peripheral blood stem cells, and sequential IL2.","groups":[{"description":"Patients receive melphalan IV over 2-3 hours on day -2 and an infusion of IL-2-treated autologous or syngeneic peripheral blood stem cells on day 0. Beginning on day 0, patients also receive IL-2 IV continuously over 5 days followed by 2 days off. Treatment with IL-2 repeats weekly for 4 weeks. Beginning 1 month later, patients undergo maintenance therapy comprising interferon alfa SC 3 times a week in the absence of disease progression or unacceptable toxicity.\n\nmelphalan: Given IV\n\nrecombinant interferon alfa: Given SC\n\naldesleukin: Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion\n\nin vitro-treated peripheral blood stem cell transplantation: Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion","id":"OG000","title":"Immunotherapy Treatment"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Of the 36 patients, 20 patients were \\<56 years old and these 20 patients are used to determine this outcome measure.","reportingStatus":"POSTED","timeFrame":"First 100 days post-transplant","title":"Number of Patients <56 Years Old Experiencing Grade 3-4 Regimen Related Toxicity","type":"SECONDARY","unitOfMeasure":"Participants"}